Events & Trainings

Current meetings, workshops, education

Academic Events

As a specialist scientific organisation, we hold many challenging events every year.

In a two-year cycle, the AGAH holds an acclaimed scientific congress in Germany, where relevant topics that interest our members are discussed – alternating with a scientific event with one of our partner organisations, AHPPI in UK, Bapu in Belgium or Association Française de Pharmacologie Translationelle (AFPT) -Le Club Phase I in France.

In addition, scientific workshops are held on special topics and there is a yearly national discussion round together with the BfArM, where mostly safety-relevant matters in early-phase clinical studies are discussed. The programme is rounded off with training courses, entitled Introductory or Applied Workshops for young scientists and a training programme specifically for study nurses.

  • DETAILS

    AGAH Mebinar | Patient Engagement in Early Phase Trials

    Digital Event  |  Jan 14 - Jan 14, 2026  |  17:30 – 19:00

    – Involvement of patients in the planning of development concepts as well as in specific aspects of clinical trials

  • DETAILS

    AGAH Conference 2026

    Haus am Dom - Katholische Akademie Rabanus Maurus  |  Feb 24 - Feb 26, 2026

    "Optimism, Courage, and Pragmatism – Human Pharmacology 2030"

  • DETAILS

    AGAH Workshop | Physiology-Based Pharmacokinetic (PBPK) model application

    Haus am Dom - Katholische Akademie Rabanus Maurus  |  Feb 24 - Feb 24, 2026  |  13:00 – 17:30

    in Model-Informed Drug Development (MIDD) -As part of the AGAH Conference. Can also be booked individually.-

  • DETAILS

    11th German Pharm-Tox Summit

    Partner-Event  |  Heinrich Heine University Düsseldorf  |  Mar 17 - Mar 20, 2026

    92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)

  • DETAILS

    28th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting

    Leonardo Weimar  |  Apr 23 - Apr 25, 2026

    This meeting will take place at Hotel Leonardo Weimar under the auspices of AGAH (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V.) and starts with a joint Dinner on 23 April 2026. The scientific programme begins on Friday morning, 24 April 2026 and ends on Saturday, 25 April 2026 at lunchtime.

  • DETAILS

    AGAH Workshop Toxic Truths and Dosing Dilemmas:

    SocraTec R&D Oberursel  |  May 7 - May 8, 2026  |  13:00 – 13:00

    Navigating Early CNS Drug Development

  • DETAILS

    Introductory Course in Exploratory Medicines Development – Part I online (6 half-days)

    Digital Event  |  Oct 22 - Nov 6, 2026

    This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

  • DETAILS

    Introductory Course in Exploratory Medicines Development – Part II face2face

     |  Nov 24 - Nov 27, 2026

    This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

AGAH e.V.
AGAH Mebinar | Patient Engagement in Early Phase Trials

– Involvement of patients in the planning of development concepts as well as in specific aspects of clinical trials

Jan 14 - Jan 14, 2026  |  17:30 – 19:00
-To be held in English-

The involvement of patients in the planning of development concepts and in concrete aspects of clinical trials in Phases II to IV — including the patient-centred communication of study results — has, at least in theory, become an established standard at the European and global level.

In practice, however, there are still considerable gaps and a lack of knowledge regarding appropriate approaches.
The advantages, the necessity, and the potential challenges of involving healthy volunteers in the design and planning of Phase I studies have so far received very little attention.

A major European survey conducted by EUFEMED on this topic has produced interesting and partly unexpected results. It therefore seems worthwhile to discuss this option in concrete terms — not only for ethical reasons, but also from a practical perspective.

In this Mebinar, we would like to explore together whether, and in what ways, the inclusion of volunteers could become an advantage for the field of human pharmacology in Germany.

Please feel free to submit your questions in advance by 9 January 2026 via the registration form

Speaker and in Dialogue with

Dr Ingrid Klingmann, Pharmaplex bv, Wezembeek-Oppem 


Please feel free to submit your questions in advance by 9 January 2026 via the registration form.

Download Programm_AGAH_Mebinar_14-01-2026.pdf
Registration Information

AGAH Member - 0 EUR
Guest - 40 EUR

Registrations welcome until 12 January 2026 (= access details will be sent)

Online Registration
Additional Information
AGAH_Mebinar_Terms_of_Registration.pdf
FAQ_AGAH_Mebinar.pdf
Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
AGAH Conference 2026

"Optimism, Courage, and Pragmatism – Human Pharmacology 2030"

Feb 24 - Feb 26, 2026
Become a Sponsor and/or Exhibitor

We kindly invite you to support us as an exhibitor and/or sponsor to help making this significant event a success and enhance the experience for all participants. We offer a range of sponsorship and exhibition options, each accompanied by promotional benefits for your company. Please refer to the brochure for more details. Please request these from our Conferenc office: agah-meetings@csihamburg.de

By sponsoring this event, your Company will expand visibility among key opinion leaders in early-phase development, regulatory authorities, ethics committees, and industry professionals. This is an excellent opportunity to showcase your commitment to advancing innovative medicines and supporting state-of-the-art clinical research.

PROGRAMME SCHEDULE AT A GLANCE

Thuesday, 24th February 2026
Pre-Meeting Workshop | 13:00–17:30
"Physiology-Based Pharmacokinetic (PBPK) model application in Model-Informed Drug Development (MIDD)"

AGAH Mitgliederversammlung/General Assembly | 19:00

Wednesday, 25th February 2026 | 09:00–18:00
Session 1 | Session 2 | Session 3
Conference Get-Together | 18:00–20:30

Thursday, 26th February 2026 | 07:30–14:00
AGAH Breakfast Session – Meet the Expert
Session 4 | Session 5 | Session 5
Concluding, Recap and Farewell

Download conference fees and programme PDF:

Download AGAH_Conference_2026_Announcement.pdf
Registration Information

Early registration fees: until 31th October 2025


Registration Link:

Online Registration
CALL FOR ABSTRATCS – Deadline Extension until 17 November 2025

The Organizing Team of the AGAH Conference 2026 invites abstracts for poster presentation at the conference dealing with any of the following aspects of medicines development in humans.
• Model-Informed Drug Development – Progress and Outlook
• Dose Selection for Phase 2 and Phase 3 – Optimal and Optimus
• Overly Complex Early Phase Trials – Disruptive Proposals for Improvement
• Artificial Intelligence Impacting Clinical Pharmacology – A Dynamic Field of   Opportunities
• Regulatory Enablers of Innovative Early Medicines Development

The early registration fee will be reduced by 100 € if you present a poster at the Annual Conference. Please submit your abstract as a pdf using this template:

Abstract_submision_template_AGAH_Conference_2026_writeable.pdf
Event Location
Haus am Dom - Katholische Akademie Rabanus Maurus
Domplatz 3
https://hausamdom-frankfurt.de/
Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
AGAH Workshop | Physiology-Based Pharmacokinetic (PBPK) model application

in Model-Informed Drug Development (MIDD) -As part of the AGAH Conference. Can also be booked individually.-

Feb 24 - Feb 24, 2026  |  13:00 – 17:30
Program Information

Programme Draft by:

AGAH Conference

Registration Information

Early registration fees: until 31th October 2025

-As part of the AGAH Conference. Can also be booked individually.-

Online Registration
Event Location
Haus am Dom - Katholische Akademie Rabanus Maurus
Domplatz 3
https://hausamdom-frankfurt.de/
Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
11th German Pharm-Tox Summit

92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)

Mar 17 - Mar 20, 2026
Place your research on the stage

Welcome to the 11th German Pharm-Tox Summit 2026
in cooperation with
the Association for Applied Human Pharmacology (AGAH),
and the Dutch Society of Toxicology (NVT)

Join us in shaping the future of pharmacology and toxicology. Submit an abstract and take the opportunity to present your findings to the plenum. By submitting your abstract you become part of the scientific program and get the chance to share your scientific expertise with your colleagues!
All abstracts will be published as a supplement of "Naunyn-Schmiedeberg's Archives of Pharmacology" (Springer Verlag). 
Your contribution may be selected for a poster prize or a young investigator award.

Take your chance – Submit your abstracts by 1 October 2025!

https://gpts-kongress.de/program-abstracts/abstract-submission

Registration Information

Veranstalter

 •    German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
•    German Society for Pharmacology (DGP)
•    German Society for Toxicology (GT)
•    German Society for Clinical Pharmacology and Therapy (DGKliPha)


Tagungsleitung

Univ.-Prof. Dr. med. Maria Grandoch, M.Sc.
Prof. Dr. Jens W. Fischer
Prof. Dr. rer. nat. Gerhard Fritz

Fachgebiete

Pharmacology, clinical pharmacology and toxicology General Medical Research Food & Product Safety Pharmacy, Pharmaceutical/Bio/Medical Chemistry Biotechnology Environmental Medicine

Kongresssprache

Englisch

Online Registration
Additional Information

www.gpts-kongress.de

Event Location
Heinrich Heine University Düsseldorf
Building: 22.01,
Roy Lichtenstein,
40225 Düsseldorf
Event Manager
Conventus Congressmanagement & Marketing GmbH
gpts@conventus.de
28th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting

This meeting will take place at Hotel Leonardo Weimar under the auspices of AGAH (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V.) and starts with a joint Dinner on 23 April 2026. The scientific programme begins on Friday morning, 24 April 2026 and ends on Saturday, 25 April 2026 at lunchtime.

Apr 23 - Apr 25, 2026
Program Information

Programme to follow


Registration Information

Start you registration from 15 November 2025 - Book your seat in time - number of participants is limited.

The conference fee includes also the accommodation costs, further information is available within the registration.


PLEASE START YOUR

Online Registration
Awards

Young scientists: Hans Günter Schäfer Award
Generous donations have enabled the Organizing Committee of the PK/PD Expert Meeting to reward outstanding contributions to the PK/PD field by young scientists with the Hans Günter Schäfer Award (cash amount of 1.000 EUR plus free meeting participation incl. travel expenses) issued in memory of the original initiator of the PK/PD Expert Meeting. The award is kindly sponsored by the Frankfurt Foundation Quality of Medicines.
If you are a Doctorate student or young scientist (less than two years after PhD degree) and want to apply for this award, send your peer-reviewed, published manuscript as a pdf file to Tobias Pähler - tobias.paehler[@]sanofi.com. Manuscript submissions must be accompanied by a brief description (500 words maximum) of how your manuscript fits into the overall scientific context of the respective research area, with a specific focus on its innovation, methodology and clinical or in vivo relevance. Submission deadline: 1 February 2026; applicant notification by 10 March 2026. The winner will be announced on the website of the PK/PD Expert Meeting and will present their work as part of the main conference.

Master / Doctorate students: Best presentation award
Three young PK/PD scientists will be given the opportunity to give an oral presentation of their work (5 minutes) as part of the main conference. All invited presenters will participate free of charge (incl. accommodation). The best presenter will be honored and will receive the “Young Scientist Best Presentation Award” plus reimbursement of travel expenses.
If you are a Master thesis or Doctorate student and want to apply for this award, send an abstract (500 words maximum) to Tobias Pähler - tobias.paehler[@]sanofi.com.
Submission deadline: 1 February 2026; applicant notification by 10 March 2026.
Three applicants will be selected and invited for presentation.

Application to both awards is possible. However, expectation is that a dedicated abstract is written for the ‘Best presentation award’, submission of one complete manuscript for both categories will not be accepted.


General Terms of Registration

General-Terms-of-Registration_AGAH_PK_PD_Expertmeeting2026.pdf
Event Location
Leonardo Weimar
Belvederer Allee 25,
99425 Weimar
www.leonardo-hotels.com
Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
AGAH Workshop Toxic Truths and Dosing Dilemmas:

Navigating Early CNS Drug Development

May 7 - May 8, 2026  |  13:00 – 13:00
Program Information

AGAH Workshop on the Early Safety Assessment of CNS-Active Drugs – 
Concepts, Strategies, and Potential Pitfalls


The development of CNS-active drugs presents unique challenges in safety assessment, requiring robust strategies to identify and mitigate risks early in clinical development. This AGAH workshop will provide an in-depth exploration of translational considerations, risk management strategies, and lessons learned - including those that shaped the 2018 revision of the EMA guideline - designed to critically evaluate and refine decision-making in early-phase trials.

Key questions to be discussed include:
1.    Which results from early safety assessments are most robust from a translational perspective?
2.    What strategies best support human risk/benefit assessment in CNS drug development?
3.    How have regulatory guidelines evolved to improve risk mitigation in first-in-human studies?

Preliminary schedule

Thursday
1:00 - 6:00 pm
Friday
8:30 - 1:00 pm

Real-world examples, both discontinued (such as BIA 10-2474) and marketed drugs, will illustrate these key questions. While focusing on CNS-active drugs, the principles and strategies explored in this workshop offer valuable insights applicable across all therapeutic areas. 


-Detailed programme to follow-


Registration Information

Participation fee

750 € Regular
500 € Member* 
500 € Junior Scientist up to the age of 30
250 € Member of Regulatory Agencies or ethics committees

*of the following EUFEMED society: AGAH, AHPPI, AFPT - Le Club Phase 1, HEALIXIA, POLFEMED

START YOUR:

Online Registration
GENERAL TERMS AND CONDITIONS OF REGISTRATION
General-Terms-of-Registration_AGAH_WS_Toxic_Truths_Dosing_Dilemmas_2026.pdf
Event Location
SocraTec R&D Oberursel
Im Setzling 35,
61440 Oberursel
https://socratec-pharma.de/
Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
Introductory Course in Exploratory Medicines Development – Part I online (6 half-days)

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Oct 22 - Nov 6, 2026
Program Information

Learning Outcomes

On successful completion of Part 1, students should be able to demonstrate an understanding / knowledge of the following:

  • principal steps in drug development - from compound selection to marketing application and beyond
  • pertinent issues involved in the undertaking of early clinical research
  •  specific aspects of how to set-up and conduct early phase clinical trials
  •  regulation of medicines in Europe
  • development and review of compound-specific information to ensure adherence to scientific, medical, ethical, and legal provisions
  • integration of pertinent available scientific information into an IB and a clinical trial protocol
  • principles of trial design, protocol submission and clinical conduct
  • selection of appropriate trial population
  • most common early phase clinical trials and their specific requirements
  • assessment and evaluation of safety data from clinical trials
  • relevance of formulation properties and in vitro characteristics of the trial medication for design and planning of an early phase clinical trial
  • basics of pharmacokinetics
  • defining pharmacokinetic (PK) endpoints for early phase clinical trials
  • method validation according to good clinical (GCP) and good laboratory (GLP) practise practical aspects of bioequivalence trials
Registration Information

to follow

Part I - Online

Day 1    22 October 2026 13:00–18:00

Day 2    23 October 2026 13:00–17:00

Day 3    29 October 2026 13:00–18:00

Day 4    30 October 2026 13:00–17:00

Day 5     5 November 2026 13:00–18:00

Day 6     6 November 2026 13:00–17:00

Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
Introductory Course in Exploratory Medicines Development – Part II face2face

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Nov 24 - Nov 27, 2026
Program Information

Learning Outcomes

On successful completion of Part 2, students should be able to demonstrate an understanding / knowledge of the following:

  • nonclinical pharmacology and toxicology
  • molecular basis of drug actions
  • allometric scaling and dose proportionality assessments based on characteristic PK data
  • defining pharmacodynamic (PD) endpoints and biomarkers
  • differentiating between primary and secondary PK and PD endpoints
  • How to design an early clinical pharmacology developmant plan
  • planning and management of a first-in-man trial
  • principles of data management and information flow
  • principles of reporting and publication
  • principles of medical statistics
  • characteristic issues involved in the development of biologicals and biosimilars

This AGAH course meets the standards for high-quality postgraduate education and training in Medicines Development established by PharmaTrain and has been awarded a PharmaTrain Recognition. The previous courses  were accredited 3 ECTS (Parts I plus II)

Registration Information

to follow

Additional Information

Day 1     24 November 2026, 09:00–18:30

Day 2     25 November 2026, 09:00–18:00

Day 3     26 November 2026, 09:00–17:45

Day 4     27 November 2026, 09:00–15:00

Mandatory Test (conducted online)

                  1 December 2026, 17:00–19:00

Event Location
Oberursel (Germany)
Event Manager
CSi Hamburg GmbH
+49 40 30770300
agah-meetings@csihamburg.de
https://csihamburg.de
For quick access, insert your search phrase here.

Full commitment for our members

Our office is committed to working for our tasks and our members. You can reach us during normal office hours by phone or, of course, at any time by e-mail.

We will be happy to answer any questions you may have.

The Association for Applied Human Pharmacology (AGAH e.V.)

Association for Applied Human Pharmacology (AGAH)
Arbeitsgemeinschaft für Angewandte Humanpharmakologie e.V.

Sekretariat/Mitgliederverwaltung

Adress: Goernestraße 30
20249 Hamburg

Phone: +49 40 . 30 77 20 97
E-Mail: info@agah.eu
Einstellungen zur Barrierefreiheit

Weitere Informationen zu unseren Maßnahmen zur Verbesserung der Barrierefreiheit finden Sie in der Erklärung zur Barrierefreiheit .